Latest News

Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

10 March 2022

  • Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapy
  • Data show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET) along with downregulation...

Read more

KOL Event - 14 March 2022 at 11am ET

04 March 2022

Read more

StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

01 March 2022

New York, March 1, 2022 - Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER...

Read more

Tiziana Life Science's Presentation at the Bio CEO & Investor Conference 2022

11 February 2022

Read more

Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference

10 February 2022

February 10, 2022, New York, NY – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer and Chief...

Read more

Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease

04 February 2022

  • - Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study

New York, February 4, 2022 – Tiziana Life Sciences Ltd (Nasdaq: TLSA)...

Read more

Page 2 of 34 Previous Next